Key result
The 50% inhibitory concentrations in the EXCA-1 assay were 0.025 IU/ml for dalteparin, 0.13 U/ml for danaparoid, 0.12 IU/ml for heparin, 1.3 microg/ml for fondaparinux, 2.4 ng/ml for hirudin, and 1 microg/ml for argatroban.
Why the study?
Can the extrinsic coagulation activity assay (EXCA) monitor the efficiency of various plasmatic anticoagulants in normal plasma?
Population
Unfrozen pooled normal citrated plasma
Comparison
Increasing concentrations of dalteparin… vs Normal thrombin generation without inhibitors
Design
Preclinical
Authors
Loading...
EXCA may monitor anticoagulant efficiency in plasma; hypothesis-generating and should not yet change practice.
Can the extrinsic coagulation activity assay (EXCA) monitor the efficiency of various plasmatic anticoagulants in normal plasma?
The extrinsic coagulation activity assay (EXCA) can effectively monitor the efficiency of clinically used plasmatic anticoagulants by determining their 50% inhibitory concentrations.
T. Stief (2007) studied this question. dalteparin, danaparoid, heparin, fondaparinux, hirudin, or argatroban was evaluated on 50% inhibitory concentrations in EXCA-1. The 50% inhibitory concentrations in the EXCA-1 assay were 0.025 IU/ml for dalteparin, 0.13 U/ml for danaparoid, 0.12 IU/ml for heparin, 1.3 microg/ml for fondaparinux, 2.4 ng/ml for hirudin, and 1 microg/ml for argatroban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: